生产企业：Reunion Neuroscience
FT-104 (luvesilocin, RE104) is an investigational short-duration serotonergic psychedelic prodrug of 4-OH-DiPT developed by Reunion Neuroscience for the treatment of postpartum depression. It received FDA Breakthrough Therapy Designation in 2025 based on positive Phase 2 results.
FT-104 (luvesilocin, RE104) is an investigational short-duration serotonergic psychedelic prodrug of 4-OH-DiPT developed by Reunion Neuroscience for the treatment of postpartum depression. It received FDA Breakthrough Therapy Designation in 2025 based on positive Phase 2 results.
共 1 项相关疾病
